Abstract: The present invention provides for novel compositions of anti-CTLA-4 antibodies comprising a chelating agent. Also provided are method of treating diseases and conditions with novel compositions of CTLA-4 antibodies, including various neoplasia conditions.

Abstract: The present invention is directed towards a lyophilized or reconstituted multi-antigen or multicomponent immunogenic composition comprising at least one antigen isolated from a staphylococcal bacterium, and methods of making the same.

Abstract: The present invention is directed to stable liquid growth hormone formulations that remain stable after physical agitation, and after exposure to one or more freeze-thaw events. Formulations of the present invention can be stored long term at a variety of temperatures, even frozen. In the present invention, a combination of buffer and stabilizing agents, including a non-ionic surfactant (e.g., polysorbate 20), a polymer stabilizer (e.g., polyethylene glycol), and other optional stabilizers combine to provide unexpected stability to aqueous formulations of a growth hormone (e.g., human growth hormone).

Abstract: A pharmaceutical composition comprises, in powder form, (a) at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, for example parecoxib sodium, in a therapeutically effective total amount constituting about 30% to about 90% by weight, (b) a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and optionally (c) other parenterally acceptable excipient ingredients in a total amount not greater than about 10% by weight, of the composition. The composition is reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution. A lyophilization process is provided for preparation of such a composition.

Abstract: The present invention relates to anti-MAdCAM antibody compositions comprising a chelating agent, and methods of treating inflammatory disease in a subject.

Abstract: The present invention provides for novel compositions of anti-CTLA-4 antibodies comprising a chelating agent. Also provided are method of treating diseases and conditions with novel compositions of CTLA-4 antibodies, including various neoplasia conditions.

Abstract: The present invention provides for compositions of anti-M-CSF antibodies comprising a chelating agent and/or histidine. Also provided are methods of treating M-CSF-mediated disorders with pharmaceutical formulations of anti-M-CSF anti-bodies, including inflammatory diseases and neoplasia disorders.

Abstract: The present invention is directed to stable liquid growth hormone formulations that remain stable after physical agitation, and after exposure to one or more freeze-thaw events. Formulations of the present invention can be stored long term at a variety of temperatures, even frozen. In the present invention, a combination of buffer and stabilizing agents, including a non-ionic surfactant (e.g., polysorbate 20), a polymer stabilizer (e.g., polyethylene glycol), and other optional stabilizers combine to provide unexpected stability to aqueous formulations of a growth hormone (e.g., human growth hormone).

Abstract: A pharmaceutical composition that is substantially free of water comprises at least one orally deliverable dosage unit comprising a therapeutically effective amount of a sulfonamide prodrug and, where the prodrug is readily degradable ex vivo, has means to inhibit such degradation prior to oral administration. Illustratively the prodrug is parecoxib or a water-soluble salt thereof, and the composition has means to inhibit conversion of the parecoxib to valdecoxib. A method of treating or preventing a COX-2 mediated disorder in a subject comprises (a) dissolving at least one dosage unit of such a composition in a pharmaceutically acceptable aqueous vehicle to form a solution, and (b) orally administering the solution to the subject before substantial precipitation of insoluble matter occurs in the solution.

Abstract: A pharmaceutical composition comprises, in powder form, (a) at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, for example parecoxib sodium, in a therapeutically effective total amount constituting about 30% to about 90% by weight, (b) a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and optionally (c) other parenterally acceptable excipient ingredients in a total amount not greater than about 10% by weight, of the composition. The composition is reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution. A lyophilization process is provided for preparation of such a composition.

Abstract: The present invention provides new and structurally diverse particulates for use in magnetic resonance imaging and X-ray contrast imaging of body organs and tissues having the following general formula:Ca.sub.n M.sub.m X.sub.r Y.sub.swherein M is a paramagnetic ion or stoichiometric mixture of metal ions having a valence of 2+ or 3+; X is a simple anion; Y is a tetrahedral oxyanion, or mixtures thereof; m is an integer greater than or equal to 1; n is an integer greater than or equal to 1; r and s are integers and are adjusted as needed to provide charge neutrality; and further comprising a polyalkoxy compound.Methods for using and making particles of the invention are also disclosed.

Abstract: The present invention provides new and structurally diverse particulates for use in magnetic resonance imaging and X-ray contrast imaging of body organs and tissues having the following general formula:Ca.sub.n M.sub.m X.sub.r Y.sub.swherein M is a paramagnetic ion or stoichiometric mixture of metal ions having a valence of 2+ or 3+; X is a simple anion; Y is a tetrahedral oxyanion, or mixtures thereof; m is an integer greater than or equal to 1; n is an integer greater than or equal to 1; r and s are integers and are adjusted as needed to provide charge neutrality; and further comprising a polyalkoxy compound.Methods for using and making particles of the invention are also disclosed.